Skip to main content
. 2020 Jun 5:doaa054. doi: 10.1093/dote/doaa054

Fig. 4.

Fig. 4

Distribution of ranking priority for esophagogastric cancer resections across centers from round 1 and 2 of the survey during the COVID-19 pandemic. (A) Prioritization factors. (B) Case vignettes. *For Figure 4B, the definition of each levels are as follows: level 1 (curative therapy with a high [>50%] chance of success); level 2 (curative therapy with an intermediate (15–50%) chance of success); level 3 (noncurative therapy with a high [>50%] chance of >1 year of life extension); level 4 (curative therapy with a low [0–15%] chance of success or noncurative therapy with an intermediate [15–50%] chance of >1 year life extension); level 5 (noncurative therapy with a high [>50%] chance of palliation/temporary tumor control but <1 year life extension); and level 6 (noncurative therapy with an intermediate [15–50%] chance of palliation or temporary tumor control and <1 year life extension).